Axsome Therapeutics AXSM Cash & Equivalents
Cash & Equivalents at other companies
Other financials
Where this comes from
Reported directly by Axsome Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue.
The official record: Axsome Therapeutics’s 10-Q, filed May 4, 2026, on SEC EDGAR. View the filing →
Ask your AI about Axsome Therapeutics's cash & equivalents.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Axsome Therapeutics's cash & equivalents?
- Axsome Therapeutics (AXSM) reported cash & equivalents of $305.11M in Q1 2026.
- How has Axsome Therapeutics's cash & equivalents changed year-over-year?
- Axsome Therapeutics's cash & equivalents increased by 1.4% year-over-year, from $300.91M to $305.11M.
- What is the long-term trend for Axsome Therapeutics's cash & equivalents?
- Over 5 years (2020 to 2025), Axsome Therapeutics's cash & equivalents has grown at a 11.9% compound annual growth rate (CAGR), from $183.88M to $322.93M.
- What does cash & equivalents mean?
- The total amount of cash and highly liquid investments the company has available for immediate use.
- How do you interpret cash & equivalents?
- An increase suggests improved liquidity and longer operational runway, while a decrease may indicate high cash burn from R&D or the need for future capital raises.
- How does cash & equivalents compare across companies?
- Biotech peers typically maintain high cash balances relative to assets to support multi-year clinical trial cycles.